Table 3.
Comparison of clinical features based on histological subtype
| Characteristics | DLBCL No. (%) |
MALT No. (%) |
BL No. (%) |
MCL No. (%) |
FL No. (%) |
PTCL-U No. (%) |
EATL No. (%) |
ENKTL No. (%) |
P value |
|---|---|---|---|---|---|---|---|---|---|
| Number of cases | 386 | 61 | 31 | 19 | 7 | 34 | 25 | 18 | |
| Median age (range) | 56 (15-92) | 55 (15-80) | 47 (15-78) | 60 (42-78) | 52 (39-81) | 49 (15-78) | 51 (23-75) | 47 (32-72) | 0.002 |
| Age > 60, % | 160 (41.5) | 22 (36.1) | 7 (22.6) | 10 (52.6) | 3 (42.9) | 11 (32.4) | 7 (28.0) | 5 (27.8) | 0.246 |
| Male, % | 240 (62.2) | 32 (52.5) | 25 (80.6) | 13 (68.4) | 4 (57.1) | 24 (70.6) | 17 (68.0) | 12 (66.7) | 0.273 |
| Performance status ≥ 2, % | 60 (15.6) | 6 (9.8) | 5 (16.1) | 0 (0.0) | 1 (14.3) | 9 (26.5) | 6 (24.0) | 3 (16.7) | 0.218 |
| Lugano stage IV, % | 94 (24.4) | 7 (11.5) | 17 (54.8) | 15 (78.9) | 3 (42.9) | 15 (44.1) | 8 (32.0) | 9 (50.0) | < 0.001 |
| Increased serum LDH, % | 150 (39.9) | 5 (8.5) | 23 (76.7) | 4 (21.1) | 1 (14.3) | 12 (36.4) | 8 (34.8) | 7 (38.9) | < 0.001 |
| Presence of B symptoms, % | 75 (19.5) | 7 (11.5) | 7 (22.6) | 3 (15.8) | 1 (14.3) | 12 (35.3) | 9 (36.0) | 6 (35.3) | 0.048 |
| Extranodal involvement ≥ 2, % | 93 (24.3) | 3 (5.4) | 18 (58.1) | 9 (47.4) | 2 (28.6) | 10 (29.4) | 10 (41.7) | 10 (55.6) | < 0.001 |
| IPI HI/H, % | 93 (24.5) | 5 (8.9) | 15 (48.4) | 7 (36.8) | 1 (14.3) | 9 (26.5) | 6 (26.1) | 4 (22.2) | 0.008 |
| Bone marrow invasion, % | 20 (5.2) | 4 (6.6) | 7 (22.6) | 5 (26.3) | 0 (0.0) | 3 (8.8) | 3 (12.0) | 1 (5.6) | < 0.001 |
| Intestinal obstruction, % | 69 (17.8) | 7 (11.5) | 6 (19.4) | 0 (0.0) | 2 (28.5) | 4 (11.8) | 4 (16.0) | 4 (22.2) | 0.398 |
| Bleeding, % | 8 (2.0) | 2 (3.3) | 1 (3.2) | 0 (0.0) | 0 (0.0) | 1 (2.9) | 1 (4.0) | 0 (0.0) | 0.964 |
| Perforation, % | 19 (4.9) | 1 (1.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (5.9) | 3 (12.0) | 0 (0.0) | 0.194 |
| Small intestine, % | 104 (26.9) | 14 (23.0) | 11 (35.5) | 0 (0.0) | 2 (28.6) | 13 (38.2) | 10 (40.0) | 8 (44.4) | < 0.001 |
| Ileocecal region, % | 187 (48.4) | 19 (31.1) | 9 (29.0) | 3 (15.8) | 3 (42.9) | 7 (20.6) | 2 (8.0) | 1 (5.6) | < 0.001 |
| Large intestine, % | 73 (18.9) | 21 (34.4) | 5 (16.1) | 5 (26.3) | 2 (28.6) | 5 (14.7) | 10 (40.0) | 4 (22.2) | < 0.001 |
| Multiple intestinal lesions, % | 22 (5.7) | 7 (11.5) | 6 (19.4) | 11 (57.9) | 0 (0.0) | 9 (26.5) | 3 (12.0) | 5 (27.8) | < 0.001 |
LDH: lactate dehydrogenase; IPI: International Prognostic Index; HI: high-intermediate; H: high; DLBCL: diffuse large B-cell lymphoma; MALT: extranodal marginal zone B-cell lymphoma; BL: Burkitt lymphoma; PTCL-U: peripheral T-cell lymphoma, unspecified; EATL: enteropathy-associated T-cell lymphoma; MCL: mantle cell lymphoma; ENKTL: extranodal natural killer/T-cell lymphoma; FL: follicular lymphoma